267 related articles for article (PubMed ID: 16945529)
21. Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Lan JS; Xie SS; Li SY; Pan LF; Wang XB; Kong LY
Bioorg Med Chem; 2014 Nov; 22(21):6089-104. PubMed ID: 25282654
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.
Li Y; Peng P; Tang L; Hu Y; Hu Y; Sheng R
Bioorg Med Chem; 2014 Sep; 22(17):4717-25. PubMed ID: 25082512
[TBL] [Abstract][Full Text] [Related]
23. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
24. Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Tang H; Zhao LZ; Zhao HT; Huang SL; Zhong SM; Qin JK; Chen ZF; Huang ZS; Liang H
Eur J Med Chem; 2011 Oct; 46(10):4970-9. PubMed ID: 21871694
[TBL] [Abstract][Full Text] [Related]
25. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
[TBL] [Abstract][Full Text] [Related]
27. Tryptoline-3-hydroxypyridinaldoxime conjugates as efficient reactivators of phosphylated human acetyl and butyrylcholinesterases.
Renou J; Loiodice M; Arboléas M; Baati R; Jean L; Nachon F; Renard PY
Chem Commun (Camb); 2014 Apr; 50(30):3947-50. PubMed ID: 24599312
[TBL] [Abstract][Full Text] [Related]
28. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
29. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
30. Butyryl- and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents.
Savelev SU; Okello EJ; Perry EK
Phytother Res; 2004 Apr; 18(4):315-24. PubMed ID: 15162368
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
Granica S; Kiss AK; Jarończyk M; Maurin JK; Mazurek AP; Czarnocki Z
Arch Pharm (Weinheim); 2013 Nov; 346(11):775-82. PubMed ID: 24123207
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Caricati-Neto A; D'angelo LC; Reuter H; Hyppolito Jurkiewicz N; Garcia AG; Jurkiewicz A
Eur J Pharmacol; 2004 Oct; 503(1-3):191-201. PubMed ID: 15496314
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Zurek E; Szymański P; Mikiciuk-Olasik E
Drug Res (Stuttg); 2013 Mar; 63(3):137-44. PubMed ID: 23447117
[TBL] [Abstract][Full Text] [Related]
34. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Schwarthoff S; Tischer N; Sager H; Schätz B; Rohrbach MM; Raztsou I; Robaa D; Gaube F; Arndt HD; Winckler T
Bioorg Med Chem; 2021 Sep; 46():116355. PubMed ID: 34391122
[TBL] [Abstract][Full Text] [Related]
36. Potent AChE and BChE inhibitors isolated from seeds of Peganum harmala Linn by a bioassay-guided fractionation.
Yang Y; Cheng X; Liu W; Chou G; Wang Z; Wang C
J Ethnopharmacol; 2015 Jun; 168():279-86. PubMed ID: 25862961
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of novel 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(substituted/-nonsubstituted benzal)hydrazone derivatives and acetylcholinesterase and butyrylcholinesterase inhibitory activities in vitro.
Utku S; Gökçe M; Orhan I; Sahin MF
Arzneimittelforschung; 2011; 61(1):1-7. PubMed ID: 21355440
[TBL] [Abstract][Full Text] [Related]
38. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
39. Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
Khorana N; Changwichit K; Ingkaninan K; Utsintong M
Bioorg Med Chem Lett; 2012 Apr; 22(8):2885-8. PubMed ID: 22425563
[TBL] [Abstract][Full Text] [Related]
40. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Martinez A; Castro A
Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
